Cargando…
MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300380/ http://dx.doi.org/10.1016/j.annonc.2022.05.179 |
| _version_ | 1784751200562839552 |
|---|---|
| author | Okamoto, Akinao Hidetsugu, Fujigaki Chisako, Iriyama Naoe, Goto Hideyuki, Yamamoto Keichiro, Mihara Yoko, Inaguma Yasuo, Miura Katsuya, Furukawa Yukiya, Yamamoto Yoshiki, Akatsuka Senji, Kasahara Kotaro, Miyao Okamoto, Masataka Saito, Kuniaki Tomita, Akihiho |
| author_facet | Okamoto, Akinao Hidetsugu, Fujigaki Chisako, Iriyama Naoe, Goto Hideyuki, Yamamoto Keichiro, Mihara Yoko, Inaguma Yasuo, Miura Katsuya, Furukawa Yukiya, Yamamoto Yoshiki, Akatsuka Senji, Kasahara Kotaro, Miyao Okamoto, Masataka Saito, Kuniaki Tomita, Akihiho |
| author_sort | Okamoto, Akinao |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9300380 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93003802022-07-21 MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients Okamoto, Akinao Hidetsugu, Fujigaki Chisako, Iriyama Naoe, Goto Hideyuki, Yamamoto Keichiro, Mihara Yoko, Inaguma Yasuo, Miura Katsuya, Furukawa Yukiya, Yamamoto Yoshiki, Akatsuka Senji, Kasahara Kotaro, Miyao Okamoto, Masataka Saito, Kuniaki Tomita, Akihiho Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2022-07 2022-07-21 /pmc/articles/PMC9300380/ http://dx.doi.org/10.1016/j.annonc.2022.05.179 Text en Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Okamoto, Akinao Hidetsugu, Fujigaki Chisako, Iriyama Naoe, Goto Hideyuki, Yamamoto Keichiro, Mihara Yoko, Inaguma Yasuo, Miura Katsuya, Furukawa Yukiya, Yamamoto Yoshiki, Akatsuka Senji, Kasahara Kotaro, Miyao Okamoto, Masataka Saito, Kuniaki Tomita, Akihiho MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title | MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title_full | MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title_fullStr | MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title_full_unstemmed | MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title_short | MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
| title_sort | mo30-1 factors critical for the acquisition of antibody after sars-cov-2 vaccination in malignant lymphoma patients |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300380/ http://dx.doi.org/10.1016/j.annonc.2022.05.179 |
| work_keys_str_mv | AT okamotoakinao mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT hidetsugufujigaki mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT chisakoiriyama mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT naoegoto mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT hideyukiyamamoto mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT keichiromihara mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT yokoinaguma mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT yasuomiura mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT katsuyafurukawa mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT yukiyayamamoto mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT yoshikiakatsuka mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT senjikasahara mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT kotaromiyao mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT okamotomasataka mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT saitokuniaki mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients AT tomitaakihiho mo301factorscriticalfortheacquisitionofantibodyaftersarscov2vaccinationinmalignantlymphomapatients |